Pharmacogenetics and pharmacogenomics: Role of mutational analysis in anti-cancer targeted therapy

A. Savonarola, R. Palmirotta, F. Guadagni, F. Silvestris

Research output: Contribution to journalArticle

Abstract

The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.

Original languageEnglish
Pages (from-to)277-286
Number of pages10
JournalPharmacogenomics Journal
Volume12
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Pharmacogenetics
Neoplasms
Pharmaceutical Preparations
Therapeutics
Safety
Enzymes
Research
Genes

Keywords

  • alcohol dependence
  • CRH
  • GABA
  • glutamate
  • logistic regression
  • neurotransmitter system

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Pharmacogenetics and pharmacogenomics : Role of mutational analysis in anti-cancer targeted therapy. / Savonarola, A.; Palmirotta, R.; Guadagni, F.; Silvestris, F.

In: Pharmacogenomics Journal, Vol. 12, No. 4, 08.2012, p. 277-286.

Research output: Contribution to journalArticle

Savonarola, A. ; Palmirotta, R. ; Guadagni, F. ; Silvestris, F. / Pharmacogenetics and pharmacogenomics : Role of mutational analysis in anti-cancer targeted therapy. In: Pharmacogenomics Journal. 2012 ; Vol. 12, No. 4. pp. 277-286.
@article{bfdc8c9839754d7396cc28cffbcc67c9,
title = "Pharmacogenetics and pharmacogenomics: Role of mutational analysis in anti-cancer targeted therapy",
abstract = "The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.",
keywords = "alcohol dependence, CRH, GABA, glutamate, logistic regression, neurotransmitter system",
author = "A. Savonarola and R. Palmirotta and F. Guadagni and F. Silvestris",
year = "2012",
month = "8",
doi = "10.1038/tpj.2012.28",
language = "English",
volume = "12",
pages = "277--286",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacogenetics and pharmacogenomics

T2 - Role of mutational analysis in anti-cancer targeted therapy

AU - Savonarola, A.

AU - Palmirotta, R.

AU - Guadagni, F.

AU - Silvestris, F.

PY - 2012/8

Y1 - 2012/8

N2 - The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.

AB - The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.

KW - alcohol dependence

KW - CRH

KW - GABA

KW - glutamate

KW - logistic regression

KW - neurotransmitter system

UR - http://www.scopus.com/inward/record.url?scp=84864363160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864363160&partnerID=8YFLogxK

U2 - 10.1038/tpj.2012.28

DO - 10.1038/tpj.2012.28

M3 - Article

C2 - 22760589

AN - SCOPUS:84864363160

VL - 12

SP - 277

EP - 286

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 4

ER -